{
  "id": "601c4ff61cb411341a000022",
  "type": "yesno",
  "question": "Is proton beam therapy used for treatment of craniopharyngioma?",
  "ideal_answer": "Yes, proton beam therapy is used for treatment of craniopharyngioma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25487038",
    "http://www.ncbi.nlm.nih.gov/pubmed/29404243",
    "http://www.ncbi.nlm.nih.gov/pubmed/32086697",
    "http://www.ncbi.nlm.nih.gov/pubmed/26295365",
    "http://www.ncbi.nlm.nih.gov/pubmed/29459099",
    "http://www.ncbi.nlm.nih.gov/pubmed/25260976",
    "http://www.ncbi.nlm.nih.gov/pubmed/29932288",
    "http://www.ncbi.nlm.nih.gov/pubmed/32387488",
    "http://www.ncbi.nlm.nih.gov/pubmed/31860822",
    "http://www.ncbi.nlm.nih.gov/pubmed/32129277",
    "http://www.ncbi.nlm.nih.gov/pubmed/30257123",
    "http://www.ncbi.nlm.nih.gov/pubmed/34078637",
    "http://www.ncbi.nlm.nih.gov/pubmed/16580494",
    "http://www.ncbi.nlm.nih.gov/pubmed/29520496",
    "http://www.ncbi.nlm.nih.gov/pubmed/24222710",
    "http://www.ncbi.nlm.nih.gov/pubmed/25052561",
    "http://www.ncbi.nlm.nih.gov/pubmed/30108004",
    "http://www.ncbi.nlm.nih.gov/pubmed/34049281",
    "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
    "http://www.ncbi.nlm.nih.gov/pubmed/16630407"
  ],
  "snippets": [
    {
      "text": " The majority of children had adjuvant therapy comprising proton beam therapy (18/59; 30.5%) or conventional radiotherapy (16/59; 27.1%).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31860822",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proton Therapy for Craniopharyngioma - An Early Report from a Single European Centre.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29459099",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AIMS: Proton beam therapy (PBT) is being increasingly used for craniopharyngioma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29459099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "MATERIALS AND METHODS: Between August 2013 and July 2016, 18 patients with craniopharyngiomas were treated with 54\u00a0Cobalt Gray Equivalent (CGE) in 30 fractions over 6 weeks at our centre.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29459099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Our early results are encouraging and comparable with the limited literature on PBT for craniopharyngioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29459099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "All of the other patients underwent proton-beam radiotherapy with no documented tumor growth (median follow-up: 20 months; range 5.1-29.9\u00a0months).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29520496",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Where aggressive subtotal resection is achieved, patients should be closely followed, with radiation initiated at the time of progression or recurrence-ideally via proton beam therapy, although three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and stereotactic radiosurgery are very appropriate in a range of circumstances, governed by access, patient age, disease architecture, and character of the recurrence.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29404243",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " This study examined parental distress in a sample of families of patients with Cp treated with proton beam therapy to identify factors for targeting psychological intervention.PROCEDURE: Prior to (n\u00a0=\u00a096) and 1 year after (n\u00a0=\u00a073) proton therapy, parents of children diagnosed with Cp (9.81\u00a0\u00b1\u00a04.42 years at baseline; 49% male) completed a self-report measure of distress, the Brief Symptom Inventory (BSI).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29932288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Diagnoses included medulloblastoma, craniopharyngioma, ependymoma, glial tumors, germ cell tumors, and others.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30108004",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Initial experience with proton beam therapy in childhood-onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30257123",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monte Carlo simulations were used to assess secondary neutron doses received by patients treated with proton therapy for ocular melanoma and craniopharyngioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24222710",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Secondary neutron doses in proton therapy treatments of ocular melanoma and craniopharyngioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24222710",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AIMS: Proton beam therapy (PBT) is being increasingly used for craniopharyngioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29459099",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "LTS: Published reports suggest a benefit to proton beam therapy for use in tumors of the skull base, including craniopharyngiomas, chordomas, skull-base sarcomas, and unresectable meningiomas.CONC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In recent years, proton therapy (PT), with its physical properties of heavy ion beam, that is, Prague peak phenomenon, has been more frequently used in patients with craniopharyngioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052561",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: We compared proton beam therapy (PBT) with intensity modulated radiation therapy (IMRT) for pediatric craniopharyngioma in terms of disease control, cyst dynamics, and toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052561",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proton therapy for craniopharyngioma in adults: a protocol for systematic review and meta-analysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078637",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We hereby report a case of a 7-year-old boy with a craniopharyngioma which had been subtotally resected and was subsequently treated with modern pencil beam proton therapy under high-precision image guidance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32129277",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pencil beam scanning proton therapy for the treatment of craniopharyngioma complicated with radiation-induced cerebral vasculopathies: A dosimetric and linear energy transfer (LET) evaluation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32387488",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "tial experience with proton beam therapy in childhood-onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment. R",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30257123",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: We compared proton beam therapy (PBT) with intensity modulated radiation therapy (IMRT) for pediatric craniopharyngioma in terms of disease control, cyst dynamics, and toxic",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052561",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND PURPOSE: This study analyses the dosimetric and dose averaged Linear Energy transfer (LETd) correlation in paediatric craniopharyngioma (CP) patients with and without radiation-induced cerebral vasculopathies (RICVs) treated with pencil beam scanning (PBS) pro",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32387488",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: The authors compared survival and multiple comorbidities in children diagnosed with craniopharyngioma who underwent gross-total resection (GTR) versus subtotal resection (STR) with radiation therapy (RT), either intensity-modulated radiation therapy (IMRT) or proton beam therapy (P",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34049281",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proton Therapy for Craniopharyngioma - An Early Report from a Single European Centre",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29459099",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "s. Some studies have shown that PT has advantages in the treatment of craniopharyngioma in adu",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078637",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Postoperative cerebral glucose metabolism in pediatric patients receiving proton therapy for craniopharyngioma",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26295365",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Clinical equipoise: Protons and the child with craniopharyngioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25487038",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "skull base. More public attention has been given to proton beam therapy due to the increasing number of centers now in operation or in the planning stages for offering this treatment option.METHODS: We reviewed the physical properties of protons and the clinical studies performed to justify their use in the management of skull-base tumors and determine the benefits of proton beam therapy.RESULTS: Published reports suggest a benefit to proton beam therapy for use in tumors of the skull base, including craniopharyngiomas, chordomas, skull-base sarcomas, and unresectable meningiomas.CONCLUSIONS: Use of proton beam th",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27556661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: We report the results of the early cohort of patients treated for craniopharyngioma with combined proton-photon irradiation at the Massachusetts General Hospital and the Harvard Cyclotron Laboratory.METHODS AND MATERIALS: Between 1981 and 1988, 15 patients with craniopharyngioma were treated in part or entirely with fractiona",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16580494",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "UNLABELLED: This retrospective preliminary review evaluated the efficacy and toxicity of fractionated proton radiotherapy in the management of pediatric craniopharyngioma.METHODS: Sixteen patients, aged 7-34 years, were treated with p",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16630407",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "population. We evaluated the outcomes of all adult craniopharyngioma patients treated at our institution using proton therapy to report outcomes for disease control, treatment-related toxicity, and tumor response.METHODS: We analyzed 14 adult patie",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32086697",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Proton radiation has been used safely and effectively for medulloblastoma, primitive neuro-ectodermal tumors, craniopharyngioma, ependymoma, germ cell intracranial tumors, low-grade glioma, retinoblastoma, rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma and other bone sarcomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25260976",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ontroversial. The purpose of this study was to evaluate the efficacy and safety of PT for craniopharyngioma in adults.METHODS AND ANALYSIS: We will search six databases (MEDLINE, EMBASE, Web of Science, the Cochrane Library, Amed, Scopus), clinical research registration websites and grey literature, aiming to identify randomised controlled trials (RCTs) on PT for craniopharyngioma in adults between 1",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34078637",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}